Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV001553088 | SCV001773894 | uncertain significance | not provided | 2022-04-11 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
| Ambry Genetics | RCV002449365 | SCV002734361 | uncertain significance | Inborn genetic diseases | 2016-10-05 | criteria provided, single submitter | clinical testing | The p.A771V variant (also known as c.2312C>T), located in coding exon 9 of the ATRX gene, results from a C to T substitution at nucleotide position 2312. The alanine at codon 771 is replaced by valine, an amino acid with similar properties. This variant was previously reported in the SNPDatabase as rs376906761. Based on data from the NHLBI Exome Sequencing Project (ESP), the T allele has an overall frequency of approximately 0.01% (1/10554). This amino acid position is poorly conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since clinical data for this variant is limited at this time, its clinical significance is unclear. |
| Labcorp Genetics |
RCV001827461 | SCV003462626 | benign | Alpha thalassemia-X-linked intellectual disability syndrome | 2023-11-21 | criteria provided, single submitter | clinical testing | |
| Natera, |
RCV001827461 | SCV002087337 | uncertain significance | Alpha thalassemia-X-linked intellectual disability syndrome | 2020-06-08 | no assertion criteria provided | clinical testing |